Literature DB >> 12942541

PKC-zeta is required for angiotensin II-induced activation of ERK and synthesis of C-FOS in MCF-7 cells.

Antonella Muscella1, Simona Greco, Maria Giovanna Elia, Carlo Storelli, Santo Marsigliante.   

Abstract

We examined the signalling pathways responsible for the Ang II induction of growth in MCF-7 human breast cancer cells. Ang II in MCF-7 cells induced: (a) the translocation from the cytosol to membrane and nucleus of atypical protein kinase C-zeta (PKC-zeta) but not of PKC-alpha, -delta, - epsilon and -eta; (b) the expression of c-fos mRNA and protein; (c) the phosphorylation of the extracellular signal-regulated protein kinases 1 and 2 (ERK1/2). All these effects were due to the activation of the Ang II type I receptor (AT1) since they were blocked by the AT1 antagonist losartan. The Ang II-stimulated ERK1/2 phosphorylation was blocked by (a) high doses of staurosporine, inhibitor of PKC-zeta, and by a synthetic myristoylated peptide with sequences based on the endogenous PKC-zeta pseudosubstrate region (zeta-PS); (b) PD098059, a mitogen-activated protein kinase kinase inhibitor (MAPKK/MEK); and, moreover, (c) the inhibitors of phosphoinositide 3-kinases (PI3K), LY294002 and wortmannin, thus indicating that PI3K may act upstream of ERK1/2. The Ang II-evoked c-fos induction was blocked only by high doses of staurosporine and by zeta-PS whilst PD098059, LY294002 and wortmannin were ineffective, thus indicating that c-fos induction is not due to ERK1/2 activity. When the epidermal growth factor-receptor (EGFR) tyrosine kinase activity was inhibited by the use of its inhibitor AG1478, Ang II was still able to induce ERK1/2 phosphorylation and c-fos expression, therefore proving that the transactivation of EGFR was not required for these Ang II effects in MCF-7 cells. The previously reported proliferation of MCF-7 cells induced by Ang II was blocked by PD098059 and by wortmannin in a dose-dependent manner, thereby indicating that in MCF-7 cells the PI3K and ERK pathways mediate the mitogenic signalling of AT1. Our results suggest that in MCF-7 cells Ang II activates multiple signalling pathways involving PKC-zeta, PI3K and MAPK; of these pathways only PKC-zeta appears responsible for the induction of c-fos. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12942541     DOI: 10.1002/jcp.10336

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  12 in total

Review 1.  Lessons from in vitro studies and a related intracellular angiotensin II transgenic mouse model.

Authors:  Julia L Cook; Richard N Re
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-12-14       Impact factor: 3.619

2.  Atypical protein kinase C activity is required for extracellular matrix degradation and invasion by Src-transformed cells.

Authors:  Elena M Rodriguez; Elizabeth E Dunham; G Steven Martin
Journal:  J Cell Physiol       Date:  2009-10       Impact factor: 6.384

3.  G alpha(q) acts as an adaptor protein in protein kinase C zeta (PKCzeta)-mediated ERK5 activation by G protein-coupled receptors (GPCR).

Authors:  Carlota García-Hoz; Guzmán Sánchez-Fernández; Maria Teresa Díaz-Meco; Jorge Moscat; Federico Mayor; Catalina Ribas
Journal:  J Biol Chem       Date:  2010-03-03       Impact factor: 5.157

Review 4.  The renin-angiotensin system and cancer: old dog, new tricks.

Authors:  Amee J George; Walter G Thomas; Ross D Hannan
Journal:  Nat Rev Cancer       Date:  2010-10-22       Impact factor: 60.716

5.  ERK activation and cell growth require CaM kinases in MCF-7 breast cancer cells.

Authors:  John M Schmitt; Ellen Abell; Andrea Wagner; Monika A Davare
Journal:  Mol Cell Biochem       Date:  2009-09-18       Impact factor: 3.396

6.  Progesterone receptor A-regulated gene expression in mammary organoid cultures.

Authors:  Sarah J Santos; Mark D Aupperlee; Jianwei Xie; Srinivasan Durairaj; Richard Miksicek; Susan E Conrad; Jeffrey R Leipprandt; Ying S Tan; Richard C Schwartz; Sandra Z Haslam
Journal:  J Steroid Biochem Mol Biol       Date:  2009-04-19       Impact factor: 4.292

7.  AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist.

Authors:  Daniel R Rhodes; Bushra Ateeq; Qi Cao; Scott A Tomlins; Rohit Mehra; Bharathi Laxman; Shanker Kalyana-Sundaram; Robert J Lonigro; Beth E Helgeson; Mahaveer S Bhojani; Alnawaz Rehemtulla; Celina G Kleer; Daniel F Hayes; Peter C Lucas; Sooryanarayana Varambally; Arul M Chinnaiyan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-01       Impact factor: 11.205

8.  Effect of angiotensin receptor blockade on prevention and reversion of tamoxifen-resistant phenotype in MCF-7 cells.

Authors:  Soha Namazi; Ebrahim Sahebi; Javad Rostami-Yalmeh; Mansooreh Jaberipour; Mahboobeh Razmkhah; Ahmad Hosseini; Rita Arabsolghar
Journal:  Tumour Biol       Date:  2014-10-11

9.  Selective apoptosis of pluripotent mouse and human stem cells by novel ceramide analogues prevents teratoma formation and enriches for neural precursors in ES cell-derived neural transplants.

Authors:  Erhard Bieberich; Jeane Silva; Guanghu Wang; Kannan Krishnamurthy; Brian G Condie
Journal:  J Cell Biol       Date:  2004-11-15       Impact factor: 10.539

10.  A new platinum(II) compound anticancer drug candidate with selective cytotoxicity for breast cancer cells.

Authors:  A Muscella; C Vetrugno; F P Fanizzi; C Manca; S A De Pascali; S Marsigliante
Journal:  Cell Death Dis       Date:  2013-09-12       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.